No Data
No Data
ANGI, MLKN and KOD Are Among After Hour Movers
NewAmsterdam Pharma to Present New Analysis From the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination With Ezetimibe at 2024 American College of Cardiology Congress
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical co
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients With HeFH And/or ASCVD
-- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination ("FDC") as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD ri
NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations
NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
NAARDEN, The Netherlands and MIAMI, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical com
No Data